Nathan DM. DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014;37:9–16.CrossrefGoogle Scholar
Orchard TJ, Nathan DM, Zinman B, Cleary P, Brillon D, et al. Writing Group for the DCCT/EDIC Research Group. Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. J Am Med Assoc 2015;313:45–53.CrossrefGoogle Scholar
Urakami T, Morimoto S, Kubota S, Funaki S, Harada K. Usefulness of the long-acting insulin analogue glargine in basal-bolus therapy for Japanese children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2007;20:807–15.PubMedGoogle Scholar
Ludvigsson J, Samuelsson U. Continuous insulin infusion (CSII) or modern type of multiple daily injections (MDI) in diabetic children and adolescents a critical review on a controversial issue. Pediatr Endocrinol Rev 2007;5:666–78.PubMedGoogle Scholar
Mochizuki M, Kikuchi T, Urakami T, Kikuchi N, Kawamura T, et al. Japanese Study Group of Insulin Therapy for Childhood Adolescent Diabetes (JSGIT). Improvement in glycemic control through changes in insulin regimens: findings from a Japanese cohort of children and adolescents with type 1 diabetes. Pediatr Diabetes 2016;18:435–42.Google Scholar
Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, et al. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabet 2009;10(Suppl 12):71–81.CrossrefGoogle Scholar
Plavšić L, Mitrović K, Todorović S, Vuković R, Milenković T, et al. Glycaemic control and prevalence of hypoglycaemic events in children and adolescents with type 1 diabetes mellitus treated with insulin analogues. Vojnosanit Pregl 2014;71:817–20.Web of SciencePubMedCrossrefGoogle Scholar
Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, et al. Short acting insulin analogs versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2004;4:CD003287.Google Scholar
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Weinzimer S, Miller K, Beck R, Xing D, et al. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care 2010;33:17–22.Web of ScienceCrossrefGoogle Scholar
Japan Diabetes Clinical Data Management Group. Mean HbA1c (NGSP) in each year. 2013. Available at: http://jddm.jp/data/index-2013.html#data03.
Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, et al. Current state of type 1 diabetes treatment in the US: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971–8.CrossrefWeb of ScienceGoogle Scholar
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, Buckingham B, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359: 1464–76.PubMedCrossrefGoogle Scholar
Keller M, Attia R, Beltrand J, Djadi-Prat J, Nguyen-Khoa T, et al. Insulin regimens, diabetes knowledge, quality of life, and HbA1c in children and adolescents with type 1 diabetes. Pediatr Diabetes 2017;18:340–7.PubMedWeb of ScienceCrossrefGoogle Scholar
Neu A, Lange K, Barrett T, Cameron F, Dorchy H, et al. Classifying insulin regimens difficulties and proposal for comprehensive new definitions. Pediatr Diabetes 2015;16:402–6.PubMedWeb of ScienceCrossrefGoogle Scholar
Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006;2:CD003287.Google Scholar
Cummins E, Royle P, Snaith A, Greene A, Robertson L, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14:1–181.Web of ScienceGoogle Scholar
Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010;1:CD005103.Web of ScienceGoogle Scholar
Fatourechi MM, Kudva YC, Murad MH, Elamin MB, Tabini CC, et al. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009;94: 729–40.CrossrefPubMedGoogle Scholar
Pańkowska E, Błazik M, Dziechciarz P, Szypowska A, Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes 2009;10:52–8.Web of ScienceCrossrefPubMedGoogle Scholar
Phillip M, Danne T, Shalitin S, Buckingham B, Laffel L, et al. Consensus Forum Participants. Use of continuous glucose monitoring in children and adolescents. Pediatr Diabetes 2012;13:215–28.CrossrefPubMedGoogle Scholar
Sulmont V, Lassmann-Vague V, Guerci B, Hanaire H, Leblanc H, et al. French pediatric PUMP group. Access of children and adolescents with type 1 diabetes to insulin pump therapy has greatly increased in France since 2001. Diabetes Metab 2011;37:59–63.CrossrefPubMedGoogle Scholar
Sherr JL, Hermann JM, Campbell F, Foster NC, Hofer SE, et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia 2016;59:87–91.Web of ScienceCrossrefPubMedGoogle Scholar
Sulmont V, Souchon PF, Gouillard-Darnaud C, Fartura A, Salmon-Musial AS, et al. Metabolic control in children with diabetes mellitus who are younger than 6 years at diagnosis: continuous subcutaneous insulin infusion as a first line treatment? J Pediatr 2010;157:103–7.PubMedCrossrefGoogle Scholar
About the article
Published Online: 2018-12-05
Published in Print: 2019-01-28
Author contributions: Y.Y. and T.K. researched data, equally contributed to the discussion as the first authors and wrote the manuscript. T.U. researched data and wrote the manuscript. K.T., G.S., H.M., Y.A and K.K. contributed to the discussion. S.A. and S.S. were the chairpersons of the 2008 and 2013 cohorts, respectively, and researched data and contributed to the discussion. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This study was funded by Japan Diabetes Foundation 2015.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.